Biomarker Elevations Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome after CD19-Directed CAR-T Therapy in Children and Young Adults with Acute B-Lymphoblastic Leukemia | Synapse
March 3, 2026
Biomarker Elevations Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome after CD19-Directed CAR-T Therapy in Children and Young Adults with Acute B-Lymphoblastic Leukemia
Key Points
Elevated biomarkers indicate the occurrence of hemophagocytic lymphohistiocytosis after therapy.
Biomarker elevations were observed in children and young adults post CD19-directed CAR-T therapy.
Analysis of clinical data from leukemia patients highlights important associations with immune responses.
Findings underscore the necessity for monitoring biomarkers to manage potential complications effectively.